Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: A randomised phase II study

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1797-1806

  Khoo, Kei Siong ^a   Manzoor Zaidi, Syed Hasan ^b   Srimuninnimit, Vichien ^c   Song, Santai ^d   Nair, Reena ^e   Ngelangel, Corazon A ^f   Bustam, Anita ^g   Reece, William H H ^h   Lehnert, Manfred ⁱ  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Baquai Institute of Oncology   (Pakistan)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Beijing 307 Hospital   (China)

^e TATA MEMORIAL HOSPITAL   (India)

^f PHILIPPINE GENERAL HOSPITAL   (Philippines)

^g UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^h Clinical Outcomes and Research Institute   (Australia)

ⁱ Eli Lilly Asian Operations   (Hong Kong)

Author keywords

Gemcitabine; Metastatic breast cancer; Taxanes

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TIME; TREATMENT FAILURE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TAXOIDS; TREATMENT FAILURE;

EID: 33746656336     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.05.001     Document Type: Article

References (34)

1. Seidman A.D., Hudis C.A., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16 (1998) 3353-3361
2. Hainsworth J.D., Burris III H.A., Erland J.B., et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16 (1998) 2164-2168
3. Briasoulis E., Karavasilis V., Anastasopoulos D., et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalating study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 10 (1999) 701-706
4. Burstein H.J., Manola J., Younger J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18 (2000) 1212-1219
5. Perez E.A., Vogel C.L., Irwin D.H., et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19 (2001) 4216-4223
6. Marchetti P., Urien S., Cappellini G.A., et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 44 (2002) S3-S13
7. Carmichael J., Possinger K., Phillip P., et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13 (1995) 2731-2736
8. Possinger K., Kauffmann M., Coleman R., et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10 (1999) 155-162
9. Brodowicz T., Kostler W.J., Möslinger R., et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. The Breast 9 (2000) 338-342
10. Blackstein M., Vogel C.L., Ambinder R., et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62 (2002) 2-8
11. Zoli W., Ricotti L., Dal Susino M., et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Brit J Cancer 81 (1999) 609-615
12. Qu G., and Perez A.E. Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol 29 Suppl. 1 (2002) 44-52
13. Sanchez P., Medina M.B., Mohedano N., et al. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann Oncol 9 Suppl. 4 (1998) 16 [Abstract]
14. Mavroudis D., Malamos N., Alexopoulos A., et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 10 (1999) 211-215
15. Fountzilas G., Nicolaides C., Bafaloukos D., et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest 18 (2000) 503-509
16. Laufman L.R., Spiridonidis C.H., Pritchard J., et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial. Ann Oncol 12 (2001) 1259-1264
17. Murad A.M., Guimaraes R.C., Aragao B.C., et al. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol 24 (2001) 264-268
18. Brugnatelli S., Danova M., De Bella M.T., et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer. Oncology 62 (2002) 33-38
19. [NCI] National Cancer Institute, Common toxicity criteria (version 2). Bethesda (MD): Division of Cancer Treatment and Diagnosis, National Cancer Institute. http://ctep.info.nih.gov/ctc3/ctc.htm; 1999 [accessed 22.04.05].
20. O'Shaughnessy J., Nag S., Calderillo-Ruiz J., et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol 22 (2003) 7 [Abstract 25]
21. Albain K.S., Nag S., Calderillo-Ruiz G., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 22 14S (2004) 510 [Abstract]
22. Seidman A.D., Berry D., Cirrincione C., et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomised for T in HER2 normal MBC. Proc Am Soc Clin Oncol 22 14S (2004) 512 [Abstract]
23. Colomer R., Llombart-Cussac A., Lluch A., et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 15 (2004) 201-206
24. Kornek G.V., Haider K., Kwasny W., et al. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 8 (2002) 1051-1056
25. Pelegri A., Calvo L., Mayordomo I.M., et al. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial. Semin Oncol 31 Suppl. 5 (2004) 20-24
26. Chan S., Friedrichs K., Noel D., et al. Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 2341-2354
27. Paridaens R., Biganzoli L., Bruning P., et al. Paclitaxel versus doxorubicin as first line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomised study with cross-over. J Clin Oncol 18 (2000) 724-733
28. Ravdin P., Erban J., Overmoyer B., et al. Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer. Eur J Cancer 1 Suppl. 5 (2003) S201 [Abstract]
29. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
30. Goh B.C., Lehnert M., Lim H.L., et al. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer. Acta Oncol 39 (2000) 225-229
31. Goh B.C., Lee S.C., Wang L.Z., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20 (2002) 3683-3690
32. Millward M.J., Boyer M.J., Lehnert M., et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14 (2003) 449-454
33. Marre F., Sanderink G.J., De Sousa G., et al. Hepatic biotransformation of docetaxel (taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56 (1996) 1296-1302
34. Lin Y., Anderson G.D., Knator E., et al. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. J Clin Pharmacol 39 (1999) 578-582